Adele GLP-1: How a Regular Patient Would Get Access to the Same Treatment

What Adele Has Actually Said About Her Weight Loss

Adele's physical transformation between 2020 and 2021 generated significant public discussion. Her documented approach is more straightforward than most tabloid coverage suggests. In her October 2021 cover interview with British Vogue, she described a routine built around boxing, weightlifting, and circuit training. She also credited the Sirtfood Diet, a plan centered on foods that activate sirtuins (proteins linked to metabolic regulation), including kale, buckwheat, red wine, and dark chocolate.

She has not, at any point in a verified public statement, confirmed using a GLP-1 receptor agonist, semaglutide, tirzepatide, or any prescription weight-loss medication.

What the Media Inferred

The GLP-1 speculation surrounding Adele is media-generated inference, not a confirmed clinical fact. Several entertainment outlets noted the speed and degree of her weight change and pointed to the concurrent rise of GLP-1 medications. That reasoning is circumstantial. Rapid physical transformation in a high-income individual with full access to personal trainers, private chefs, and medical concierge services has multiple plausible explanations that do not require a prescription medication.

Why the Distinction Matters

Attributing a specific drug to a celebrity without their confirmation can mislead patients who then arrive at a clinic with an inaccurate model of what caused someone else's results. GLP-1 medications produce meaningful weight loss, but they work alongside diet and exercise, not instead of them. A patient who expects a medication to replicate a celebrity outcome without the supporting lifestyle work is likely to be disappointed.

The clinical information below describes who GLP-1 medications are actually approved for and how to access them, regardless of what any celebrity does or does not take.

What GLP-1 Receptor Agonists Actually Are

GLP-1 stands for glucagon-like peptide-1. It is a hormone produced in the gut after eating. It signals the pancreas to release insulin, tells the liver to reduce glucose output, and, critically for weight management, signals the brain's hypothalamus to reduce appetite and slow gastric emptying. The result is reduced caloric intake with less subjective hunger.

Pharmaceutical GLP-1 receptor agonists mimic this hormone at pharmacological concentrations far above endogenous levels. Two agents are currently FDA-approved specifically for chronic weight management in adults without type 2 diabetes.

Semaglutide (Wegovy)

Semaglutide 2.4 mg subcutaneous once weekly received FDA approval for chronic weight management in June 2021 [1]. The STEP-1 trial (N=1,961) demonstrated a mean weight loss of 14.9% of body weight at 68 weeks compared with 2.4% in the placebo group (P<0.001) [2]. Participants also showed significant reductions in waist circumference, blood pressure, and fasting glucose.

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, extended these findings. Adults with established cardiovascular disease and overweight or obesity who took semaglutide 2.4 mg experienced a 20% relative risk reduction in major adverse cardiovascular events compared with placebo [3]. This is the first weight-loss drug to demonstrate a cardiovascular mortality benefit.

Tirzepatide (Zepbound)

Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. The FDA approved it for chronic weight management in November 2023 under the brand name Zepbound [4]. In SURMOUNT-1 (N=2,539), participants on the 15 mg dose lost a mean of 20.9% of body weight at 72 weeks versus 3.1% with placebo [5]. That degree of loss, sustained over 72 weeks, approaches outcomes seen with some bariatric surgical procedures.

Who Qualifies for a GLP-1 Prescription

FDA labeling and the Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy specify two eligibility tiers [6].

Tier 1. Adults with a body mass index (BMI) of 30 or above.

Tier 2. Adults with a BMI of 27 or above who also carry at least one weight-related comorbidity. Qualifying comorbidities include type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, cardiovascular disease, or nonalcoholic fatty liver disease.

Age and Pediatric Labeling

Semaglutide 2.4 mg (Wegovy) received expanded FDA approval for adolescents aged 12 and older with a BMI at or above the 95th percentile for age and sex in December 2022 [7]. Tirzepatide carries approval only for adults as of the date of this article.

Contraindications to Screen For

Both agents carry a boxed warning for a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Providers screen for these before prescribing. Pancreatitis history, severe gastrointestinal motility disorders, and pregnancy are also contraindications or cautions that require clinical judgment.

The Step-by-Step Process to Access a GLP-1 Medication

Getting a GLP-1 prescription follows the same pathway whether you heard about these drugs from a clinical journal or from a celebrity story. The steps below reflect the standard of care described in the American Association of Clinical Endocrinology's Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity [8].

Step 1. Find a Qualified Prescriber

Three pathways exist:

1. Primary care provider. Any licensed physician, nurse practitioner, or physician assistant can prescribe these medications. A primary care visit is the lowest-barrier starting point.
2. Obesity medicine specialist. Physicians board-certified through the American Board of Obesity Medicine (ABOM) have specialized training. The ABOM website lists verified diplomates by ZIP code.
3. Telehealth platform. Several regulated telehealth platforms connect patients with licensed providers who can evaluate, prescribe, and manage GLP-1 therapy remotely. HealthRX operates this model with physician oversight on every prescription. Telehealth encounters typically take 20-30 minutes and can be completed from home.

Step 2. Prepare for Your Intake Evaluation

Providers need specific information to prescribe safely. Gather the following before your appointment.

• Current weight and height (for BMI calculation)
• Recent fasting glucose or HbA1c if available
• Blood pressure readings from the past 6 months
• Current medication list, including supplements
• Personal and family history of thyroid cancer or MEN 2
• History of pancreatitis or gallbladder disease
• History of eating disorders (requires extra clinical consideration)

Some platforms order lab work as part of the intake, which may include a comprehensive metabolic panel, fasting lipid panel, HbA1c, and thyroid-stimulating hormone.

Step 3. Understand the Titration Schedule

Neither semaglutide nor tirzepatide is started at its full therapeutic dose. Gastrointestinal side effects (nausea, vomiting, constipation) are dose-dependent and most pronounced during up-titration. Standard titration schedules reduce but do not eliminate these effects.

For Wegovy (semaglutide 2.4 mg):

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

For Zepbound (tirzepatide):

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Titration continues in 2.5 mg increments every 4 weeks to a target of 10 or 15 mg weekly

Providers may slow this schedule if side effects are significant. Some patients reach maintenance dose in 16 weeks; others take 24-28 weeks.

Step 4. Manage Cost and Insurance

This is the most complicated step. Wegovy and Zepbound carry list prices between $900 and $1,400 per month in the United States. Actual out-of-pocket cost depends on insurance formulary, prior authorization requirements, and manufacturer savings programs.

Novo Nordisk offers a savings card that reduces Wegovy cost to $0 for eligible commercially insured patients. Eli Lilly offers a comparable savings card for Zepbound. Neither program is available to patients on Medicare or Medicaid.

Medicare Part D plans are currently prohibited from covering GLP-1 medications for weight loss alone under the Social Security Act. This is a known coverage gap. The Treat and Reduce Obesity Act, if passed, would amend this prohibition, but as of early 2025, it has not been signed into law.

Patients paying cash can explore 90-day supply options through discount pharmacy platforms, which may reduce the per-dose cost by 15-25%.

Step 5. Ongoing Monitoring

GLP-1 therapy is not a one-time prescription. Effective management includes follow-up at 4 weeks after initiation, then monthly during titration, and every 3 months once at maintenance dose. Monitoring typically includes weight, blood pressure, glycemic markers if applicable, and assessment for adverse effects.

The Endocrine Society guideline states: "Pharmacotherapy for obesity should be prescribed as part of a comprehensive treatment plan that includes a reduced-calorie diet, increased physical activity, and behavioral counseling" [6].

Compounded Semaglutide: What Patients Need to Know

During 2022-2024, semaglutide (Ozempic/Wegovy) appeared on the FDA's drug shortage list. This opened a legal window under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act for compounding pharmacies to produce copies. Many telehealth platforms and medical spas offered compounded semaglutide at prices 60-80% below brand-name cost.

The FDA removed semaglutide from the shortage list in May 2024, which effectively ended the legal basis for most compounded copies [9]. The agency has since issued warning letters to compounders continuing to produce copies of the commercially available product. As of the date this article was reviewed, patients should exercise caution with any platform offering compounded semaglutide at dramatically reduced prices. The FDA guidance states that outsourcing facilities and traditional compounders "may not compound drugs that are essentially a copy of an approved drug that is not on the shortage list" [9].

Tirzepatide remains on shortage as of early 2025, meaning compounded tirzepatide may still be legal in certain dispensing contexts, though the clinical evidence base applies specifically to the brand-name formulation tested in trials.

Lifestyle Factors That Determine Whether GLP-1 Therapy Works

The degree of weight loss a patient achieves on a GLP-1 medication correlates with the lifestyle foundation surrounding it. The following framework is used by HealthRX clinicians to categorize patients at intake and set realistic expectations.

Tier A patients arrive with a structured eating pattern, some existing physical activity, and sleep averaging 7 or more hours per night. Clinical experience within our practice suggests this group responds most consistently and tolerates titration with fewer interruptions.

Tier B patients have irregular eating patterns, sedentary daily activity, and sleep disruption. These patients may see slower early responses and benefit from concurrent behavioral health support. The STEP-5 trial (N=304, 104 weeks) found that patients who combined semaglutide 2.4 mg with intensive behavioral intervention maintained 15.2% weight loss at two years, versus patients in the medication-only arm who regained approximately one-third of lost weight after discontinuation [10].

Tier C patients have untreated binge eating disorder, severe food anxiety, or active psychiatric conditions affecting eating behavior. These patients require multidisciplinary evaluation before or alongside GLP-1 initiation. GLP-1 therapy alone is unlikely to produce durable results and may worsen restrictive eating patterns in susceptible individuals.

The key point across all tiers: the drug attenuates hunger. The patient still has to make food and activity choices within that attenuated hunger environment. Neither Adele's documented results nor the clinical trial outcomes occurred in isolation from lifestyle.

What Adele's Story Can and Cannot Tell Regular Patients

The media narrative around Adele's transformation has value. It moved GLP-1 medications from a niche diabetes treatment into broad public awareness. That awareness has prompted millions of people to ask their doctors about treatment options they were previously unaware of. That is a net positive for public health.

The narrative has limits. Adele has access to resources that the average patient does not: personal trainers available daily, a nutritionist, private medical care, and financial resources that eliminate cost as a barrier. Her timeline and results are not a reliable benchmark for a patient managing a full-time job, family obligations, and a $500 monthly medication budget.

Clinical trial data is a more reliable guide. STEP-1 enrolled adults with obesity across multiple countries under controlled conditions and produced a mean 14.9% weight loss [2]. That figure represents the middle of the distribution. Some patients lost considerably more; others lost less than 5%. A provider can help a specific patient understand where their individual risk factors place them on that distribution.

The Telehealth Route: What the Appointment Actually Looks Like

For patients without a primary care provider or who want faster access, telehealth is a legitimate and regulated pathway. A typical HealthRX GLP-1 intake appointment proceeds as follows.

The provider reviews the intake form, which includes BMI, comorbidities, medications, and contraindication screening. The video consultation runs approximately 20 minutes. The provider discusses realistic expectations, explains the titration schedule, answers questions about side effects, and determines whether lab work is needed before writing the prescription.

If approved, the prescription is sent to a preferred pharmacy or, in states where it is permitted, to a mail-order pharmacy that the platform works with. The first auto-injector pen arrives within 3-5 business days in most metropolitan areas.

Follow-up is scheduled at 4 weeks via asynchronous messaging or a brief video check-in. Monthly check-ins continue through titration.

The American Telemedicine Association's position is that asynchronous and synchronous telehealth encounters can meet the standard of care for chronic weight management when appropriate clinical oversight is in place [11].